Table 1.
Serum CSC-stimulating activity and MCP levels in stratified patients.*
| Stratification by response to NT (total n = 20) | ||||
|---|---|---|---|---|
|
| ||||
| pCR (n = 9) | non-pCR (n = 11) | pCR vs. non-pCR P value | ||
|
| ||||
| ALDEFLUOR+ (% of MDA-MB-231) | Pre-NT | 1.02 ± 0.19 | 1.03 ± 0.23 | >0.99 |
| Post-NT | 3.52 ± 1.36 | 1.96 ± 0.61 | 0.004 | |
| Pre vs. Post P value | 0.004 | 0.005 | ||
|
| ||||
| ESA+CD44+CD24−/low (% of BT474) | Pre-NT | 0.66 ± 0.20 | 0.68 ± 0.27 | 0.55 |
| Post-NT | 2.67 ± 0.68 | 2.01 ± 0.77 | 0.05 | |
| Pre vs. Post P value | 0.004 | 0.002 | ||
|
| ||||
| CCL2/MCP-1 (pg/ml) | Pre-NT | 109.1 ± 24.6 | 116.1 ± 34.1 | 0.52 |
| Post-NT | 222.2 ± 83.8 | 177.8 ± 54.8 | 0.23 | |
| Pre vs. Post P value | 0.004 | 0.003 | ||
|
| ||||
| CCL7/MCP-3 (pg/ml) | Pre-NT | 15.6 ± 8.1 | 14.0 ± 7.2 | 0.71 |
| Post-NT | 48.2 ± 18.1 | 37.9 ± 13.1 | 0.08 | |
| Pre vs. Post P value | 0.004 | 0.002 | ||
|
| ||||
| CCL8/MCP-2 (pg/ml) | Pre-NT | 74.7 ± 29.7 | 73.5 ± 34.5 | 0.72 |
| Post-NT | 185.9 ± 59.0 | 136.8 ± 42.8 | 0.10 | |
| Pre vs. Post P value | 0.004 | <0.001 | ||
|
| ||||
| Stratification by HER2 status (total n = 20) | ||||
|
| ||||
| TN (n = 8) | HER2+ (n = 12) | TN vs. HER2+ P value | ||
|
| ||||
| ALDEFLUOR+ (% of MDA-MB-231) | Pre-NT | 1.06 ± 0.23 | 1.00 ± 0.21 | 0.68 |
| Post-NT | 3.65 ± 1.42 | 2.00 ± 0.57 | 0.005 | |
| Pre vs. Post P value | 0.02 | <0.001 | ||
|
| ||||
| ESA+CD44+CD24−/low (% of BT474) | Pre-NT | 0.63 ± 0.30 | 0.70 ± 0.18 | 0.68 |
| Post-NT | 2.15 ± 0.89 | 2.41 ± 0.74 | 0.68 | |
| Pre vs. Post P value | 0.02 | <0.001 | ||
|
| ||||
| CCL2/MCP-1 (pg/ml) | Pre-NT | 128.8 ± 29.2 | 102.4 ± 26.0 | 0.05 |
| Post-NT | 262.1 ± 53.6 | 154.9 ± 43.3 | <0.001 | |
| Pre vs. Post P value | 0.02 | <0.001 | ||
|
| ||||
| CCL7/MCP-3 (pg/ml) | Pre-NT | 16.4 ± 7.3 | 13.7 ± 7.6 | 0.34 |
| Post-NT | 37.7 ± 16.3 | 45.7 ± 15.6 | 0.25 | |
| Pre vs. Post P value | 0.02 | <0.001 | ||
|
| ||||
| CCL8/MCP-2 (pg/ml) | Pre-NT | 98.5 ± 27.3 | 57.7 ± 22.8 | 0.002 |
| Post-NT | 207.5 ± 39.0 | 126.5 ± 38.1 | <0.001 | |
| Pre vs. Post P value | 0.008 | <0.001 | ||
*
The 20 pairs of pre- and post-NT sera in Figure 1A–B and Supplemental Figure 1A were stratified by BC’s response to NT (pCR vs. non-pCR) or HER2 status (TN vs. HER2+) before summarized for the activity to stimulate CSC populations and for levels of CCL2/7/8 in the format of mean ± standard deviation. Wilcoxon test was used to calculate the Pre vs. Post P value, whereas Mann–Whitney test was used for pCR vs. non-pCR P value and TN vs. HER2+ P value.